GlassScriptPhysician profile
Edwin Charles Chapman
NPI 1841303880
$16,208.59
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $29.68 · 2023: $331 · 2024: $246 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $13K · Travel and Lodging: $2,044 · Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $12,622.50 |
| Travel and Lodging | $2,043.89 |
| Food and Beverage | $1,389.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $15,515.83 | 2024-2025 | Brixadi |
| Indivior INC. | $376.59 | 2023-2025 | Sublocade |
| Orexo US, INC. | $84.00 | 2019-2023 | Zubsolv |
| Pfizer INC. | $48.76 | 2023-2024 | |
| Novo Nordisk INC | $47.02 | 2023-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $35.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.81 | 2019 | |
| Abbvie INC. | $26.29 | 2025 | |
| Bioventus LLC | $15.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2019 | |
| Phadia US INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.